Home » Stocks » SYBX

Synlogic, Inc. (SYBX)

Stock Price: $4.08 USD -0.02 (-0.37%)
Updated Jan 25, 2021 2:02 PM EST - Market open
Market Cap 142.47M
Revenue (ttm) 1.78M
Net Income (ttm) -57.38M
Shares Out 36.30M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $4.08
Previous Close $4.09
Change ($) -0.02
Change (%) -0.37%
Day's Open 4.11
Day's Range 3.98 - 4.14
Day's Volume 393,263
52-Week Range 1.39 - 4.27

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Investors need to pay close attention to Synlogic (SYBX) stock based on the movements in the options market lately.

PRNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined s...

Benzinga - 1 month ago

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-sp...

Other stocks mentioned: ANPC, ARPO, ARVN, VERU
PRNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced ...

PRNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced t...

PRNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 7, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced t...

Zacks Investment Research - 1 month ago

Synlogic (SYBX) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.

PRNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced ...

Seeking Alpha - 2 months ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

Shares of Synlogic (NASDAQ:SYBX) moved higher by 10.11% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 7.69% year over year to ($0.36...

PRNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported fi...

PRNewsWire - 2 months ago

CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced ...

PRNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced ...

PRNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 14, 2020 /PRNewswire/ -- Synlogic, Inc.

PRNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Synlogic, Inc.

InvestorPlace - 4 months ago

With a low capital cost and solid growth potential, many investors prefer to invest in penny stocks. Here are the top stocks to buy this year.

Other stocks mentioned: CWBHF, GNUS, OGI, WTRH
Seeking Alpha - 5 months ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

CAMBRIDGE, Mass., July 30, 2020 /PRNewswire/ -- Synlogic, Inc.

PRNewsWire - 5 months ago

CAMBRIDGE, Mass., July 28, 2020 /PRNewswire/ -- Synlogic, Inc.

PRNewsWire - 7 months ago

CAMBRIDGE, Mass., June 1, 2020 /PRNewswire/ -- Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, tod...

PRNewsWire - 8 months ago

CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) announced today that the company will host a Virtual R&D Event at 12:30 pm ET on Wednesday, May 27th, 2020. The event wil...

PRNewsWire - 8 months ago

CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, tod...

Seeking Alpha - 8 months ago

Synlogic: A Clinical-Stage Biopharma With A Good Risk/Reward Ratio

Seeking Alpha - 8 months ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2020 Results - Earnings Call Transcript

Benzinga - 8 months ago

Shares of Synlogic (NASDAQ:SYBX) rose 2.7% in pre-market trading after the company reported Q1 results.

24/7 Wall Street - 9 months ago

The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.

Other stocks mentioned: AVRO, FATE, KNSA, MRSN, NVCR, ORTX, TCRR
Seeking Alpha - 10 months ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Synlogic.

24/7 Wall Street - 1 year ago

With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be anoth...

Other stocks mentioned: CGEN, GLUU, GME, GRPN, IDXG, MEET, OGI, RTIX, ZNGA
Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Synlogic

Seeking Alpha - 1 year ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.

Market Watch - 1 year ago

Shares of Synlogic Inc. SYBX, +4.77% sank 9.3% toward a record low in premarket trading Tuesday, after the biotechnology company said it has discontinued the development of SYNB1020 for the tr...

Seeking Alpha - 1 year ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Synlogic, Inc. (SYBX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Benzinga - 1 year ago

Synlogic (NASDAQ: SYBX) reported positive data from Phase 1/2a study of SYNB1618 in patients with Phenylketonuria.

CNBC Television - 1 year ago

Ginkgo Bioworks and Synlogic to collaborate on 'living medicine'

Bioengineers are reprogramming bacteria in our bodies to create living medicine.

Benzinga - 1 year ago

Synlogic, Inc. announced a platform collaboration to speed up the development of Synlogic’s pipeline of Synthetic Biotic medicines using Ginkgo’s cell programming platform.

Zacks Investment Research - 1 year ago

Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.

Other stocks mentioned: RHHBY
Seeking Alpha - 1 year ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2019 Results - Earnings Call Transcript

About SYBX

Synlogic, a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for ... [Read more...]

Industry
Biotechnology
CEO
Aoife Brennan
Employees
76
Stock Exchange
NASDAQ
Ticker Symbol
SYBX
Full Company Profile

Financial Performance

In 2019, Synlogic's revenue was $2.22 million, a decrease of -11.75% compared to the previous year's $2.52 million. Losses were -$51.37 million, 6.07% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Synlogic stock is "Buy." The 12-month stock price forecast is 9.17, which is an increase of 125.03% from the latest price.

Price Target
$9.17
(125.03% upside)
Analyst Consensus: Buy